Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	3 Months Ended					1 Months Ended	3 Months Ended		3 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended				0 Months Ended	1 Months Ended				1 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Aug. 31, 2012	Mar. 31, 2013 Abbott Biotherapeutics Corp [Member] Product Development and Patent License Agreement [Member]	Mar. 31, 2013 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member]	Mar. 31, 2013 Abbott Biotherapeutics Corp [Member] After First Net Sales [Member] Product Development and Patent License Agreement [Member]	Mar. 31, 2013 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member]	Mar. 31, 2013 Abbott Biotherapeutics Corp [Member] Phase I Clinical Trial of a licensed product [Member] Product Development and Patent License Agreement [Member]	Feb. 28, 2002 MSKCC [Member] License agreement [Member]	Mar. 31, 2013 MSKCC [Member] License agreement [Member]	Mar. 27, 2012 MSKCC [Member] Clinical Trial Agreement [Member]	Mar. 31, 2013 Oak Ridge National Laboratory [Member]	Aug. 31, 2012 Aptiv Solutions [Member]	Mar. 31, 2013 Aptiv Solutions [Member]	Dec. 31, 2007 Aptiv Solutions [Member]	Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member]	Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] Maximum [Member]	Jun. 15, 2012 Fred Hutchinson Cancer Research Center [Member] license and sponsored research agreement [Member] Minimum [Member]	Jul. 19, 2012 Fred Hutchinson Cancer Research Center [Member] Clinical Trial Agreement [Member]	Aug. 28, 2012 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member] Patient	Aug. 31, 2012 University of Texas M.D. Anderson Cancer Center [Member] Clinical Trial Agreement [Member]	Sep. 30, 2012 Johns Hopkins University [Member] Clinical Trial Agreement [Member]	Sep. 26, 2012 Johns Hopkins University [Member] Clinical Trial Agreement [Member]	Nov. 21, 2012 University of Pennsylvania [Member] Clinical Trial Agreement [Member]	May 31, 2011 Jamess Capital Group LLC [Member] Transaction management agreement [Member]	Feb. 28, 2013 Former CEO [Member] Separation and Settlement Agreement [Member] Installment
Commitments and Contingencies (Textual)
License fee payment		$ 3,000,000
Milestones payments		7,750,000	1,500,000		750,000	750,000
Net sales in milestones payment				10,000,000										1,000,000
Description of royalty payment		The Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.						The Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.						Royalty payments of 2% of net sales will be due to FHCRC.
Technology access fee							50,000
Annual maintenance fee							50,000
Annual research funding							50,000
Purchase of radioactive material used for research and development										233,100
Project estimated cost for clinical trials of drug Ac-225-HuM195												1,859,333
Down payment of project estimated cost percentage												12.50%
Down payment for project											1,997,732	239,000	239,000
Clinical trial cost for approval of food and drug administration															23,500,000	13,200,000
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )														150,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )														250,000
Number of Patients																		24
Amount paid to each patient after Completing clinical trial									31,185								31,366	481,204			38,501	31,771
Start-up fee for clinical trial									79,623								19,749	33,946			22,847	16,000
Start-up due cost paid date									Jul. 10, 2012								Mar. 31, 2013
Monthly fee received by management firm																							12,500
Percentage of fully diluted capital stock equal to common stock																							10.00%
Warrant exercisable notice period description																							The warrants contain a provision wherein the holder may waive the 90 day exercise notice requirement by giving 65 days prior notice of such waiver.
Description of period of shares availability by exercise of warrant																							The shares available by exercise of this Warrant are also restricted and may not be sold or otherwise transfered until the earlier of twelve months from the closing date of the Pubco Transaction; or for six months after the planned Registration Statement is declared effective.
Maximum amount of out of pocket expenses																							5,000
Non - refundable institutional fee																			14,500
Annual pharmacy fee																				2,025
Amendment processing fee																				500
Consideration pursuant to agreement																								The Company will pay Mr. Talley in 2 equal installments the aggregate amount of $250,000 and a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.
Amount payable in installments under agreement																								250,000
Number of installments																								2
Performance bonus payable under agreement for service																								$ 60,000
Rent agreement termination date	Jan. 31, 2013
Notice period for termination of agreement	60 days prior to January 1, 2013
Rental agreement renewal description	The agreement automatically renews on a month-to-month basis and requires a two month notice of termination along with two month refundable deposit.